XERS — Xeris Biopharma Holdings Share News
0.000.00%
Last trade - 00:00- $1.84bn
- $1.97bn
- $291.85m
Brief: Xeris Biopharma Holdings Reaffirms 2025 Revenue Guidance Of $260-$275 Million
Xeris Biopharma Holdings Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Xeris Announces Changes To Its Board Of Directors
Xeris Biopharma Holdings Inc reports results for the quarter ended December 31 - Earnings Summary
Xeris Biopharma Holdings Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Xeris Expects To Exceed Full-Year 2024 Financial Guidance
Brief: Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Xeris Biopharma Holdings Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Xeris Biopharma Reports Q3 2024 Financial Results
Brief: Xeris Biopharma Q3 Net Income USD -15.738 Million
Xeris Biopharma Holdings Inc expected to post a loss of 9 cents a share - Earnings Preview
Xeris Biopharma Holdings Inc reports results for the quarter ended in June - Earnings Summary
Brief: Xeris Biopharma Q2 Net Income USD -15.005 Million
Xeris Biopharma Holdings Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Xeris Biopharma Holdings Promotes Kevin McCulloch To Be President, Chief Operating Officer
Brief: Xeris Biopharma Announces CEO Succession Plan
Brief: Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data Of Its Investigational Xerisol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (Xp-8121)
Xeris Biopharma Holdings Inc reports results for the quarter ended in January - Earnings Summary
Brief: Xeris Biopharma Q1 Net Income USD -18.98 Million